Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors

Zsuzsanna Suba
  • Recent Patents on Anti-Cancer Drug Discovery, October 2018, Bentham Science Publishers
  • DOI: 10.2174/1574892813666180720123732

Fundamental errors in the principles of currently used endocrine therapies

What is it about?

The fundamental errors in the principles of current endocrine therapies are debated and new aspects to the therapy of breast cancer are proposed.

Why is it important?

There are no direct correlations between high estrogen concentrations and breast cancer risk, but rather a defective ER signaling is the highest risk for breast cancer.

Perspectives

professor Zsuzsanna Suba
National Institute of Oncology Budapest

Synthetic estrogens are not ER agonists but rather they are inhibitors of the unliganded activation of ERs. The inhibition of either estrogen synthesis or a liganded activation of ERs by antiestrogen treatment may not accomplish a direct downregulation of cell proliferation, but rather it provokes a compensatory upregulation of ER signaling. In tumor cells, the stabilization of genomic machinery and self-directed death may be achieved via a balanced activation of the AF1 and AF2 domains of ERs by natural estrogen treatment.

Read Publication

http://dx.doi.org/10.2174/1574892813666180720123732

The following have contributed to this page: professor Zsuzsanna Suba